20 results on '"Brusi C"'
Search Results
2. The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers – two independent studies
- Author
-
POLLER L, IBRAHIM S, KEOWN M, PATTISON A, JESPERSEN J, EUROPEAN ACTION ON A.N.T.I.C.O.A.G.U.L.A.T.I.O.N. COLLABORATORS: MARUN S, MUNTEAN W, ASPÖCK G, BAILLEUL E, WIJNS W, MICHEL T, JOCHMANS K, CHATELAIN B, MARCELIS L, NIJS AN, JOHNSTON M, KYNDE K, SYRÄJLÄ M, SAVOLAINEN ER, IVASKA K, RAJAMÄKI A, VANHARANTA R, JUHAN I, AILLAUD MF, GUILLIN MC, HUISSE MG, SIE P, LECOMPTE T, SCHMITT Y, HARENBERG J, PLESCH W, ARONIS S, THEODOSSIADES G, TSOUKANAS B, MARKALA D, DITSA M, CAHILL M, MADDEN M, FITZGERALD H, MCCARTHY D, COLLINS B, ROONEY S, NAPARSTEK E, MARONGIU F, ERBA N, TESTA S, MARIANI G, POTÌ R, MANNUCCI PM, TRIPODI A, BADER R, PENGO V, GRESELE P, D'INCÀ M, AGENO W, TOSETTO A, HENSGENS HE, IDEMA RN, OOSTERHOUT DH, MULDER AB, HAMULYAK K, VD DUSSEN H, MUSIAL J, GAGO T, PALMEIRO A, CAMPOS M, MARQUES DIAS DA, CUNHA MONTEIRO Á, ANGELA CUNHA M, DE GAIA WN, PETERNEL P, STEGNAR M, FONTCUBERTA J, BORRELL M, REVERTER JC, SANTASUSANA PD, LOPEZ FERNANDEZ MF, MONTERO J, RIBERA CASADO C, VICENTE V, EDLUND B, EGBERG N, LÄMMLE B, ALBERIO L, DE MOERLOOSE P, REBER G, MACHIN SJ, MACKIE I, LAWRIE A, LUCKIT J, SHANKS D, DOLAN G, FLAHERTY T, LUDLAM CA, WALKER ID, LAWSON DE, TRISCOTT M, MARLAR RA, HEIT JA, WATZKE H, WEISSER B, GALLUS AS, OSMOND J, CORNET I, MUNSTER AM, LEED B, CHILLOU C, DEFARD M, HORELLOU MH, HALKIN H, LOEBSTEIN R, KIRGNER I, DENTALI F, TRAPANI LOMBARDO V, SOTTILOTTA G, CONSIGLIO P, DE MICHELE S, MOIA M, CARPENEDO M, OLIVIERO B, MANOTTI C, TASSONI MI, PALARETI G, BRUSI C, LEGNANI C, PEGORARO C, ANDRIANI C, GRAZIA CIRIGLIANO M, RIBALDI E, ABBATE R, POLI D, PERRICONE C, SCHIAVULI M, CASIERA C, LUPONE MR, ROSSI E, CRIVELLI S, BIROLINI A, PARENTE F, MIGLIETTA AM, CAMPOBASSO M, SYDOR W, KREVEL B, FERNANDEZ MA, LOZANO M, SHIACH C, BOWYER C, CHARLES F., PALARETI, GUALTIERO, COSMI, BENILDE, POLLER L, IBRAHIM S, KEOWN M, PATTISON A, JESPERSEN J, EUROPEAN ACTION ON ANTICOAGULATION. COLLABORATORS: MARUN S, MUNTEAN W, ASPÖCK G, BAILLEUL E, WIJNS W, MICHEL T, JOCHMANS K, CHATELAIN B, MARCELIS L, NIJS AN, JOHNSTON M, KYNDE K, SYRÄJLÄ M, SAVOLAINEN ER, IVASKA K, RAJAMÄKI A, VANHARANTA R, JUHAN I, AILLAUD MF, GUILLIN MC, HUISSE MG, SIE P, LECOMPTE T, SCHMITT Y, HARENBERG J, PLESCH W, ARONIS S, THEODOSSIADES G, TSOUKANAS B, MARKALA D, DITSA M, CAHILL M, MADDEN M, FITZGERALD H, MCCARTHY D, COLLINS B, ROONEY S, NAPARSTEK E, PALARETI G, MARONGIU F, ERBA N, TESTA S, MARIANI G, POTÌ R, MANNUCCI PM, TRIPODI A, BADER R, PENGO V, GRESELE P, D'INCÀ M, AGENO W, TOSETTO A, HENSGENS HE, IDEMA RN, OOSTERHOUT DH, MULDER AB, HAMULYAK K, VD DUSSEN H, MUSIAL J, GAGO T, PALMEIRO A, CAMPOS M, MARQUES-DIAS DA, CUNHA MONTEIRO Á, ANGELA CUNHA M, DE GAIA WN, PETERNEL P, STEGNAR M, FONTCUBERTA J, BORRELL M, REVERTER JC, SANTASUSANA PD, LOPEZ-FERNANDEZ MF, MONTERO J, RIBERA CASADO C, VICENTE V, EDLUND B, EGBERG N, LÄMMLE B, ALBERIO L, DE MOERLOOSE P, REBER G, MACHIN SJ, MACKIE I, LAWRIE A, LUCKIT J, SHANKS D, DOLAN G, FLAHERTY T, LUDLAM CA, WALKER ID, LAWSON DE, TRISCOTT M, MARLAR RA, HEIT JA, WATZKE H, WEISSER B, GALLUS AS, OSMOND J, CORNET I, MUNSTER AM, LEED B, CHILLOU C, DEFARD M, HORELLOU MH, HALKIN H, LOEBSTEIN R, KIRGNER I, DENTALI F, TRAPANI LOMBARDO V, SOTTILOTTA G, CONSIGLIO P, DE MICHELE S, MOIA M, CARPENEDO M, OLIVIERO B, MANOTTI C, TASSONI MI, COSMI B, BRUSI C, LEGNANI C, PEGORARO C, ANDRIANI C, GRAZIA CIRIGLIANO M, RIBALDI E, ABBATE R, POLI D, PERRICONE C, SCHIAVULI M, CASIERA C, LUPONE MR, ROSSI E, CRIVELLI S, BIROLINI A, PARENTE F, MIGLIETTA AM, CAMPOBASSO M, SYDOR W, KREVEL B, FERNANDEZ MA, LOZANO M, SHIACH C, BOWYER C, CHARLES F., Interne Geneeskunde, Biochemie, and RS: CARIM School for Cardiovascular Diseases
- Subjects
INR correction ,endocrine system ,medicine.medical_specialty ,coagulometers ,Prothrombin Time/*standard ,Reproducibility of Result ,PT ,World Health Organization ,International Normalized Ratio/*standard ,Thromboplastin ,Automation ,Laboratory/standard ,ECAA plasmas ,Predictive Value of Tests ,health services administration ,medicine ,Animals ,Humans ,heterocyclic compounds ,International Normalized Ratio ,cardiovascular diseases ,thromboplastins ,Blood Coagulation ,Reference standards ,Mathematics ,Automation, Laboratory ,Observer Variation ,Prothrombin time ,Analysis of Variance ,medicine.diagnostic_test ,business.industry ,fungi ,Reproducibility of Results ,Hematology ,Reference Standards ,Surgery ,INR Line ,Multicenter study ,Calibration ,Linear Models ,Prothrombin Time ,Cattle ,Rabbits ,Observer variation ,Nuclear medicine ,business - Abstract
The WHO scheme for prothrombin time (PT) standardization has been limited in application, because of its difficulties in implementation, particularly the need for mandatory manual PT testing and for local provision of thromboplastin international reference preparations (IRP).The value of a new simpler procedure to derive international normalized ratio (INR), the PT/INR Line, based on only five European Concerted Action on Anticoagulation (ECAA) calibrant plasmas certified by experienced centres has been assessed in two independent exercises using a range of commercial thromboplastins and coagulometers. INRs were compared with manual certified values with thromboplastin IRP from expert centres and in the second study also with INRs from local ISI calibrations.In the first study with the PT/INR Line, 8.7% deviation from certified INRs was reduced to 1.1% with human reagents, and from 7.0% to 2.6% with rabbit reagents. In the second study, deviation was reduced from 11.2% to 0.4% with human reagents by both local ISI calibration and the PT/INR Line. With rabbit reagents, 10.4% deviation was reduced to 1.1% with both procedures; 4.9% deviation was reduced to 0.5% with bovine/combined reagents with local ISI calibrations and to 2.9% with the PT/INR Line. Mean INR dispersion was reduced with all thromboplastins and automated systems using the PT/INR Line.The procedure using the PT/INR Line provides reliable INR derivation without the need for WHO ISI calibration across the range of locally used commercial thromboplastins and automated PT systems included in two independent international studies.? 2010 International Society on Thrombosis and Haemostasis.
- Published
- 2011
- Full Text
- View/download PDF
3. The D-dimer (DD) Test to Establish the Duration of Anticoagulation after a First Unprovoked Episode of Venuos Thromboembolism (VTE); the Prospective Randomized 'Prolong' Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA)
- Author
-
Palareti, G., Tosetto, A., Cosmi, B., Legnani, C., Brusi, C., Pengo, V., Ghirarduzzi, A., Pattacini, A., Testa, S., Iorio, Alfonso, and Tripodi, A.
- Published
- 2005
4. Prevention of allergic contact dermatitis from nail varnishes and hardeners
- Author
-
Giorgini, S., primary, Brusi, C., additional, Francalanci, S., additional, Gola, M., additional, and Sertoli, A., additional
- Published
- 1994
- Full Text
- View/download PDF
5. Prevention of allergic contact dermatitis with alternative products
- Author
-
Sertoli, A., primary, Francalanci, S., additional, Giorgini, S., additional, Brusi, C., additional, and Acciai, M. C., additional
- Published
- 1994
- Full Text
- View/download PDF
6. Evaluation of patch test reactions by evaporimetry and colorimetry
- Author
-
Brusi, C., primary, Giorgini, S., additional, Francalanci, S., additional, Gola, M., additional, and Sertoli, A., additional
- Published
- 1994
- Full Text
- View/download PDF
7. Allergic contact dermatitis in caterers
- Author
-
Acciai, M. C., primary, Brusi, C., additional, Francalanci, S., additional, Giorgini, S., additional, and Sertoli, A., additional
- Published
- 1993
- Full Text
- View/download PDF
8. Baseline transepidermal water loss in 3 different anatomical regions in healthy and eczematous subjects
- Author
-
Giorgini, S., primary, Brusi, C., additional, Accial, M. C., additional, Gori, L., additional, and Sertoli, A., additional
- Published
- 1992
- Full Text
- View/download PDF
9. Allergic contact dermatitis in a pastry cook
- Author
-
Gola, M., primary, Acciai, M. C., additional, Brusi, C., additional, Giorgini, S., additional, and Sertoli, A., additional
- Published
- 1989
- Full Text
- View/download PDF
10. Skin tests with fresh foods.
- Author
-
AcciaI, M.C., Brusi, C., Francalanci, S., Gola, M., and Sertoli, A.
- Subjects
- *
INGESTION , *ABSORPTION (Physiology) , *URTICARIA , *SKIN inflammation , *CONTACT dermatitis , *FOOD testing - Abstract
A 30-year-old housewife, with no personal history of atopy, had a grandmother who had died from an anaphylactic reaction to the ingestion of vegetables. Intradermal testing gave positive results to allergen extracts of certain vegetables: chick-pea, pea, soya bean and peanut. She reported two episode of acute urticaria with angioedema after the ingestion, respectively, of cooked chick peas and of a slice of chick-pea cake. Raw, soaked and chick-peas were used in order to carry out Skin Applied Food Test.
- Published
- 1991
- Full Text
- View/download PDF
11. D-dimer testing to determine the duration of anticoagulation therapy.
- Author
-
Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AWA, Tripodi A, PROLONG Investigators, Palareti, Gualtiero, Cosmi, Benilde, Legnani, Cristina, Tosetto, Alberto, Brusi, Carlotta, Iorio, Alfonso, and Pengo, Vittorio
- Abstract
Background: The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation.Methods: We performed D-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal D-dimer level did not resume anticoagulation, whereas those with an abnormal D-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years.Results: The D-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P=0.02). Thromboembolism recurred in 24 of 385 patients with a normal D-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal D-dimer level, as compared with those with a normal D-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P=0.02).Conclusions: Patients with an abnormal D-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal D-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277 [ClinicalTrials.gov].). [ABSTRACT FROM AUTHOR]- Published
- 2006
12. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: The blind, prospective CALTHRO study
- Author
-
Lelia Valdrè, Michelangelo Sartori, Carlotta Brusi, Giuliana Guazzaloca, Gualtiero Palareti, Cristina Legnani, Eleonora Conti, Gianfranco Lessiani, Giuseppina Rodorigo, Benilde Cosmi, Palareti G, Cosmi B, Lessiani G, Rodorigo G, Guazzaloca G, Brusi C, Valdré L, Conti E, Sartori M, and Legnani C.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Deep vein ,Risk Assessment ,Fibrin Fibrinogen Degradation Products ,Young Adult ,Double-Blind Method ,Predictive Value of Tests ,Risk Factors ,medicine ,Humans ,Prospective Studies ,COMPRESSION ULTRASONOGRAPHY ,Ultrasonography, Doppler, Color ,Prospective cohort study ,Aged ,Aged, 80 and over ,Immunoassay ,Venous Thrombosis ,Leg ,Chi-Square Distribution ,VENOUS THROMBEMBOLISM ,Vascular disease ,business.industry ,Venous Thromboembolism ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Thrombosis ,Surgery ,Venous thrombosis ,medicine.anatomical_structure ,Predictive value of tests ,Ambulatory ,Disease Progression ,Female ,business ,Chi-squared distribution ,Biomarkers - Abstract
SummaryThe natural history of calf deep-vein thrombosis (DVT) is still uncertain and it is debated whether it warrants to be diagnosed and treated. We aimed to investigate the complication rate of untreated isolated calf DVT (ICDVT). Symptomatic outpatients were prospectively managed with serial compression ultrasonography (SCUS). Those without proximal DVT and with likely pre-test clinical probability (PCP) or altered D-dimer received immediate subsequent complete examination of calf deep veins (CCUS) by a different operator. The result of CCUS was kept blind both to the managing doctor and the patient and disclosed after three months. Primary outcome was the rate of venous thromboembolism at three months. We examined 431 subjects (196 males; median age 68.0 years) in whom five outcomes were recorded (1.2%; 95% confidence intervals [CI]: 0.4–2.7). If CCUS results had been available, outcomes would have been recorded in 3/424 patients (0.7%; 95% CI: 0.2–2.1) with two events in subjects negative at both serial and complete CUS. ICDVT was diagnosed in 65 subjects (15.3%; 95% CI: 12–19); of whom 59 remained uneventful (one was lost to follow-up). A significant higher rate of outcomes was recorded in subjects with than without ICDVT (5/64; 7.8%; 95% CI: 3–17 vs. 3/351; 0.8%; 95% CI: 0–2; p=0.003). However, after excluding two events picked at serial CUS in subjects with ICDVT, the difference became barely significant (3/64; 4.7%; 95% CI: 1–13; p=0.049). Thrombotic evolution of untreated ICDVT in high-risk subjects may be relevant. Larger studies are needed to address this issue.
- Published
- 2010
- Full Text
- View/download PDF
13. Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients
- Author
-
Carlotta Brusi, Benilde Cosmi, Elisabetta Favaretto, Giuseppina Rodorigo, Ludovica Migliaccio, Eleonora Conti, Michelangelo Sartori, Sartori, M, Migliaccio, L, Favaretto, E, Brusi, C, Conti, E, Rodorigo, G, and Cosmi, B
- Subjects
Adult ,Male ,medicine.medical_specialty ,Venography ,MEDLINE ,ultrasonography, deep vein thrombosis ,Upper Extremity ,Upper Extremity Deep Vein Thrombosis ,Outpatients ,Internal Medicine ,Medical imaging ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Aged ,Ultrasonography ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Ultrasound ,Middle Aged ,medicine.disease ,Surgery ,Pulmonary embolism ,Clinical trial ,Venous thrombosis ,Female ,Radiology ,business - Abstract
not available
- Published
- 2015
14. D-dimer testing to determine the duration of anticoagulation therapy
- Author
-
Gualtiero, Palareti, Benilde, Cosmi, Cristina, Legnani, Alberto, Tosetto, Carlotta, Brusi, Alfonso, Iorio, Vittorio, Pengo, Angelo, Ghirarduzzi, Corrado, Pattacini, Sophie, Testa, Anthonie W A, Lensing, Armando, Tripodi, V, Pengo, Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A, and PROLONG Investigators
- Subjects
Adult ,medicine.medical_specialty ,Vitamin K ,medicine.drug_class ,Hemorrhage ,VITAMIN K ANTAGONISTS ,HYPERCOAGULABILITY ,Antithrombins ,Drug Administration Schedule ,Fibrin Fibrinogen Degradation Products ,Recurrence ,Recurrent thromboembolism ,medicine ,Humans ,Prospective Studies ,Aged ,Proportional Hazards Models ,Ultrasonography ,Aged, 80 and over ,Venous Thrombosis ,VENOUS THROMBOEMBOLISM ,business.industry ,Acenocoumarol ,Anticoagulant ,Hazard ratio ,Anticoagulants ,General Medicine ,Vitamin K antagonist ,Middle Aged ,medicine.disease ,Antiphospholipid Syndrome ,Thrombosis ,Survival Analysis ,Confidence interval ,Surgery ,Pulmonary embolism ,Discontinuation ,Anesthesia ,Warfarin ,business ,Pulmonary Embolism ,Settore MED/15 - Malattie del Sangue ,Follow-Up Studies - Abstract
Background The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of d-dimer levels may play a role in the assessment of the need for prolonged anticoagulation. Methods We performed d-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal d-dimer level did not resume anticoagulation, whereas those with an abnormal d-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years. Results: The d-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P = 0.02). Thromboembolism recurred in 24 of 385 patients with a normal d-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal d-dimer level, as compared with those with a normal d-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P = 0.02). Conclusions Patients with an abnormal d-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal d-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277.)
- Published
- 2006
15. Enhancing stroke risk prediction in patients with transient ischemic attack: insights from a prospective cohort study implementing fast-track care.
- Author
-
Barone V, Foschi M, Pavolucci L, Rondelli F, Rinaldi R, Nicodemo M, D'Angelo R, Favaretto E, Brusi C, Cosmi B, Degli Esposti D, D'Addato S, Bacchelli S, Giostra F, Pomata DP, Spinardi L, Faccioli L, Faggioli G, Donti A, Borghi C, Cortelli P, and Guarino M
- Abstract
Background and Aims: Fast-track care have been proved to reduce the short-term risk of stroke after transient ischemic attack (TIA). We aimed to investigate stroke risk and to characterize short- and long-term stroke predictors in a large cohort of TIA patients undergoing fast-track management., Methods: Prospective study, enrolling consecutive TIA patients admitted to a Northern Italy emergency department from August 2010 to December 2017. All patients underwent fast-track care within 24 h of admission. The primary outcome was defined as the first stroke recurrence at 90 days, 12 and 60 months after TIA. Stroke incidence with 95% confidence interval (CI) at each timepoint was calculated using Poisson regression. Predictors of stroke recurrence were evaluated with Cox regression analysis. The number needed to treat (NNT) of fast-track care in preventing 90-day stroke recurrence in respect to the estimates based on baseline ABCD
2 score was also calculated., Results: We enrolled 1,035 patients (54.2% males). Stroke incidence was low throughout the follow-up with rates of 2.2% [95% CI 1.4-3.3%] at 90 days, 2.9% [95% CI 1.9-4.2%] at 12 months and 7.1% [95% CI 5.4-9.0%] at 60 months. Multiple TIA, speech disturbances and presence of ischemic lesion at neuroimaging predicted stroke recurrence at each timepoint. Male sex and increasing age predicted 90-day and 60-month stroke risk, respectively. Hypertension was associated with higher 12-month and 60-month stroke risk. No specific TIA etiology predicted higher stroke risk throughout the follow-up. The NNT for fast-track care in preventing 90-day stroke was 14.5 [95% CI 11.3-20.4] in the overall cohort and 6.8 [95% CI 4.6-13.5] in patients with baseline ABCD2 of 6 to 7., Conclusion: Our findings support the effectiveness of fast-track care in preventing both short- and long-term stroke recurrence after TIA. Particular effort should be made to identify and monitor patients with baseline predictors of higher stroke risk, which may vary according to follow-up duration., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Barone, Foschi, Pavolucci, Rondelli, Rinaldi, Nicodemo, D’Angelo, Favaretto, Brusi, Cosmi, Degli Esposti, D’Addato, Bacchelli, Giostra, Pomata, Spinardi, Faccioli, Faggioli, Donti, Borghi, Cortelli and Guarino.)- Published
- 2024
- Full Text
- View/download PDF
16. The Role of Er-yag Glass Laser in Skin Resurfacing.
- Author
-
Bertossi D, Carletta LC, Fink LC, Bartolucci M, Barba G, Montanari A, Alotto M, Brusi C, and Chirumbolo S
- Subjects
- Cicatrix etiology, Cicatrix prevention & control, Cicatrix surgery, Humans, Rejuvenation, Acne Vulgaris, Hyperpigmentation, Laser Therapy adverse effects, Lasers, Solid-State therapeutic use, Skin Aging
- Abstract
Following our survey, we can appreciate that a variety of laser platforms exist to rejuvenate the skin by resurfacing the outer layer of the skin as well as heating the lower layers of the dermis. Based on reliable clinical effectiveness and a limited side effect profile, we can confirm that nonablative fractionated technologies greatly improve the appearance of lentigines, rhytids; eliminate sun damage, attenuate scarring due to acne and other causes; and treat hyperpigmentation. The Fraxel (Solta Medical) laser system delivers pulses across a wide range of density and energy levels. We determined that when increasing the pulse energy this led to an increase in thermolysis microzone depth and width without damaging the surrounding tissue. Due to its performance and various clinical applications, Fraxel laser can be optimally considered to be the gold standard for skin rejuvenation., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
17. Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients.
- Author
-
Sartori M, Migliaccio L, Favaretto E, Brusi C, Conti E, Rodorigo G, and Cosmi B
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Outpatients statistics & numerical data, Prospective Studies, Ultrasonography, Upper Extremity diagnostic imaging, Upper Extremity Deep Vein Thrombosis diagnostic imaging
- Published
- 2015
- Full Text
- View/download PDF
18. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study.
- Author
-
Palareti G, Cosmi B, Lessiani G, Rodorigo G, Guazzaloca G, Brusi C, Valdré L, Conti E, Sartori M, and Legnani C
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Chi-Square Distribution, Disease Progression, Double-Blind Method, Female, Fibrin Fibrinogen Degradation Products metabolism, Humans, Immunoassay, Male, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Risk Assessment, Risk Factors, Time Factors, Ultrasonography, Doppler, Color, Venous Thromboembolism blood, Venous Thromboembolism diagnostic imaging, Venous Thrombosis blood, Venous Thrombosis diagnostic imaging, Young Adult, Leg blood supply, Venous Thromboembolism etiology, Venous Thrombosis complications
- Abstract
The natural history of calf deep-vein thrombosis (DVT) is still uncertain and it is debated whether it warrants to be diagnosed and treated. We aimed to investigate the complication rate of untreated isolated calf DVT (ICDVT). Symptomatic outpatients were prospectively managed with serial compression ultrasonography (SCUS). Those without proximal DVT and with likely pre-test clinical probability (PCP) or altered D-dimer received immediate subsequent complete examination of calf deep veins (CCUS) by a different operator. The result of CCUS was kept blind both to the managing doctor and the patient and disclosed after three months. Primary outcome was the rate of venous thromboembolism at three months. We examined 431 subjects (196 males; median age 68.0 years) in whom five outcomes were recorded (1.2%; 95% confidence intervals [CI]: 0.4-2.7). If CCUS results had been available, outcomes would have been recorded in 3/424 patients (0.7%; 95% CI: 0.2-2.1) with two events in subjects negative at both serial and complete CUS. ICDVT was diagnosed in 65 subjects (15.3%; 95% CI: 12-19); of whom 59 remained uneventful (one was lost to follow-up). A significant higher rate of outcomes was recorded in subjects with than without ICDVT (5/64; 7.8%; 95% CI: 3-17 vs. 3/351; 0.8%; 95% CI: 0-2; p=0.003). However, after excluding two events picked at serial CUS in subjects with ICDVT, the difference became barely significant (3/64; 4.7%; 95% CI: 1-13; p=0.049). Thrombotic evolution of untreated ICDVT in high-risk subjects may be relevant. Larger studies are needed to address this issue.
- Published
- 2010
- Full Text
- View/download PDF
19. Evaporimetiy in the differentiation of allergic, irritant and doubtful patch test reactions.
- Author
-
Giorgini S, Brusi C, and Sertoli A
- Abstract
Background/aims: The aim is to evaluate, using evaporimetry, the possibility of getting further information supporting clinical reading of allergic, irritant reactions and doubtful patch test reactions., Methods: The investigation was carried out on 204 patients (182 female and 22 male, mean age 31.6 years), patch tested routinely as suspects of allergic contact dermatitis. We evaluated 326 reactions (203 allergic, 123 irritant or doubtful)., Results: Mean values pf TEWL were: for the positive allergic reactions, 7.21 (SD, 2.26) at 48 h, 15.77 (SD, 5.50) at 72 h; and for the irritant or doubtful reactions, 7.55 (SD, 1.72) at 48 h, and 5.77 (SD, 1.41) at 72 h. TEWL in the 2 reactions groups at 72 h was significantly different (p<0.01)., Conclusions: The study shows (i) concordance between the evaporimeter values and the visual score; (ii) at 72 h, the evaporimeter values are increased in the allergic reactions but not in irritant or doubtful reactions; (iii) evaporimetry in the differential diagnoses of patch test reactions was deemed useful.
- Published
- 1996
- Full Text
- View/download PDF
20. Contact sensitization to acyclovir.
- Author
-
Gola M, Francalanci S, Brusi C, Lombardi P, and Sertoli A
- Subjects
- Acyclovir administration & dosage, Administration, Topical, Adult, Female, Humans, Infusions, Intravenous, Urticaria chemically induced, Acyclovir immunology, Dermatitis, Contact immunology
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.